Sort   by:  
 Page size 
UnknownMicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
Purpose Children with acute myeloid leukemia (AML) whose disease is refractory to standard induction chemotherapy therapy or who experience relapse after initial response have dismal outcomes. We sought to comprehensively profile pediatric AML microRNA (miRNA) samples to identify dysregulated genes ...
S-EPMC5721230 | biostudies-literature
UnknownA review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.
Osteosarcoma, the most common malignant bone tumor of childhood, is a high-grade primary bone sarcoma that occurs mostly in adolescence. Standard treatment consists of surgery in combination with multi-agent chemotherapy regimens. The development and approval of imatinib for Philadelphia chromosome-...
S-EPMC3668267 | biostudies-literature
UnknownTesting of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

Background

Genz-644282 is a novel non-camptothecin topoisomerase I poison that is in clinical development.

Procedures

Genz-644282 was tested against the PPTP in vitro panel (0.1 nM to 1 µM), and in vivo using three times per week × 2 schedule repeated at day 21 at its maximum tolerate...
S-EPMC3154998 | biostudies-literature
ProteomicsProteogenomic subtyping of chronic lymphocytic leukemia identifies subgroups with contrasting clinical outcome and distinct ex-vivo drug response profile
We have performed a comprehensive proteomic analysis of clinical patient samples of chronic lymphocytic leukemia (CLL) alongside genome-, transcriptome- and ex-vivo drug response profiling. Trisomy 12 and IGHV mutation status had the strongest impact on the proteome and transcriptome; and SF3B1 muta...
ORGANISM(S): Homo sapiens (Human) 
2022-10-17 | PXD028936 | Pride
Lymphoblast B-cell Chronic lymphoblastic leukemia Proteogenomics Human Lc-ms Leukemia Cancer Clinical samples. Hirief Proteomics 
ProteomicsProteogenomic subtyping of chronic lymphocytic leukemia identifies subgroups with contrasting clinical outcome and distinct ex-vivo drug response profile
We have performed a comprehensive proteomic analysis of clinical patient samples of chronic lymphocytic leukemia (CLL) alongside genome-, transcriptome- and ex-vivo drug response profiling. Trisomy 12 and IGHV mutation status had the strongest impact on the proteome and transcriptome; and SF3B1 muta...
ORGANISM(S): Homo sapiens (Human) 
2024-06-21 | PXD017453 | Pride
Lymphoblast B-cell Chronic lymphoblastic leukemia Proteogenomics Human Lc-ms Leukemia Cancer Clinical samples. Hirief Proteomics 
UnknownTargeting epigenetic features in clear cell sarcomas based on patient-derived cell lines.

Background

Clear cell sarcomas (CCSs) are translocated aggressive malignancies, most commonly affecting young adults with a high incidence of metastases and a poor prognosis. Research into the disease is more feasible when adequate models are available. By establishing CCS cell lines from a ...
S-EPMC9884415 | biostudies-literature
ProteomicsProteogenomic subtyping of chronic lymphocytic leukemia identifies subgroups with contrasting clinical outcome and distinct ex-vivo drug response profile – DIA Validation
We have performed a comprehensive proteomic analysis of clinical patient samples of chronic lymphocytic leukemia (CLL) alongside genome-, transcriptome- and ex-vivo drug response profiling. Trisomy 12 and IGHV mutation status had the strongest impact on the proteome and transcriptome; and SF3B1 muta...
ORGANISM(S): Homo sapiens (Human) 
2022-10-19 | PXD024544 | Pride
Lymphoblast B-cell Chronic lymphoblastic leukemia Human Leukemia Cancer Proteogenomics Hirief Dia Lc-ms Clinical samples Data independent acquisition Proteomics 
UnknownProteogenomics refines the molecular classification of chronic lymphocytic leukemia.
Cancer heterogeneity at the proteome level may explain differences in therapy response and prognosis beyond the currently established genomic and transcriptomic-based diagnostics. The relevance of proteomics for disease classifications remains to be established in clinically heterogeneous cancer ent...
S-EPMC9584885 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

Background

Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.
S-EPMC8362594 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.

Background

Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.

Methods

In an open-label, ad...
S-EPMC8362592 | biostudies-literature
Sort   by:  
 Page size